JP6915774B2 - Testosterone increaser - Google Patents
Testosterone increaser Download PDFInfo
- Publication number
- JP6915774B2 JP6915774B2 JP2016111367A JP2016111367A JP6915774B2 JP 6915774 B2 JP6915774 B2 JP 6915774B2 JP 2016111367 A JP2016111367 A JP 2016111367A JP 2016111367 A JP2016111367 A JP 2016111367A JP 6915774 B2 JP6915774 B2 JP 6915774B2
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- tomato
- group
- water
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims description 100
- 229960003604 testosterone Drugs 0.000 title claims description 50
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 69
- 235000013399 edible fruits Nutrition 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 13
- 241000227653 Lycopersicon Species 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 description 69
- 230000000694 effects Effects 0.000 description 38
- 239000000843 powder Substances 0.000 description 29
- 210000001550 testis Anatomy 0.000 description 23
- 230000035882 stress Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000000284 extract Substances 0.000 description 16
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 12
- 235000012661 lycopene Nutrition 0.000 description 12
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 12
- 229960004999 lycopene Drugs 0.000 description 12
- 239000001751 lycopene Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 12
- 235000021590 normal diet Nutrition 0.000 description 11
- 230000037326 chronic stress Effects 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- -1 carboxymethyl ethyl Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000011622 Testicular disease Diseases 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 229930003448 Vitamin K Natural products 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 235000015203 fruit juice Nutrition 0.000 description 6
- 235000015193 tomato juice Nutrition 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 235000019168 vitamin K Nutrition 0.000 description 6
- 239000011712 vitamin K Substances 0.000 description 6
- 150000003721 vitamin K derivatives Chemical class 0.000 description 6
- 229940046010 vitamin k Drugs 0.000 description 6
- 102000006587 Glutathione peroxidase Human genes 0.000 description 5
- 108700016172 Glutathione peroxidases Proteins 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229940100486 rice starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 244000067456 Chrysanthemum coronarium Species 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 240000009164 Petroselinum crispum Species 0.000 description 2
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015134 garland chrysanthemum Nutrition 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000011197 perejil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940116317 potato starch Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 231100000398 testicular damage Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000020635 vitamin K rich food Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、トマト由来のテストステロン増加剤に関する。 The present invention relates to tomato-derived testosterone-increasing agents.
男性ホルモンの95%を占めるテストステロンは精巣から分泌され、男性の性腺機能はもとより骨や筋肉をつくる強力な働きがあり、女性でも卵巣等でつくられる。また、脳にも影響し、気力や認知機能に関係している。テストステロンは加齢とともに減少することが知られており、性腺機能のみならず記憶、やる気等が減退する男性更年期障害といわれる症状があらわれる。男性更年期障害は緩やかに進行する分、手遅れとなりやすい。また、男性ホルモンはストレスにより低下する。超高齢化ストレス社会において、この解決に男性ホルモン低下を予防するための食品等による男性ホルモンの強化が望まれている。 Testosterone, which accounts for 95% of male hormones, is secreted from the testes and has a powerful function of building bones and muscles as well as male gonad function, and even females make it in the ovaries. It also affects the brain and is involved in energy and cognitive function. Testosterone is known to decrease with aging, and a symptomatology called male menopause appears in which not only gonad function but also memory and motivation decline. Menopause tends to be too late as it progresses slowly. Androgens are reduced by stress. In a super-aging stress society, it is desired to strengthen male hormones with foods and the like to prevent the decrease of male hormones in order to solve this problem.
テストステロン生合成の主原料は「コレステロール」であり、その他ビタミン、亜鉛などの各種ミネラル、必須アミノ酸、アルギニンなどの血行促進成分など、様々な成分により複雑な過程を経て合成される。そのため、テストステロン生合成には、なかなか普段の食事では十分摂れないミネラル、ビタミンなどの「補酵素」と呼ばれる栄養素を意識して補給することが最も効果的である。 The main raw material for testosterone biosynthesis is "cholesterol", which is synthesized through a complicated process by various components such as vitamins, various minerals such as zinc, essential amino acids, and blood circulation promoting components such as arginine. Therefore, for testosterone biosynthesis, it is most effective to consciously supplement nutrients called "coenzymes" such as minerals and vitamins that cannot be easily taken in a normal diet.
特許文献1には、ビタミンKを有効成分として含有するテストステロン増加剤が記載されており、ビタミンK1は、青しそ、エゴマ、モロヘイヤ、パセリ、春菊等の他、トマトに含有されていることが記載されている。
しかしながら、非特許文献1によると、食品100g当たりのビタミンKの含有量は、パセリが850μg、しそが690μg、モロヘイヤが640μg、春菊(ゆで)が460μgであるのに対して、トマトでは4μgであり、トマトを用いる場合には、ビタミンKの含有量が高くなるように精製しない限り、ビタミンKの効果は期待できない。
However, according to Non-Patent
また、特許文献2には、トマト果実の2−メチル−1,3−プロパンジオール抽出物が皮膚中の活性型TGFβ−1濃度を増加させ、繊維芽細胞の増殖の促進により、抗老化効果を奏することが記載されている。
特許文献3には、トマト果実由来の非水溶性成分及びアラニンを含有する飲食品が血中アルコール濃度低減効果を奏することが記載されている。
特許文献4には、トマト果実由来の水溶性成分を含有し、実質的にリコペン含有しないトマト由来の組成物が抗血栓剤として有用であることが記載されている。
Further, in
しかしながら、トマトの乾燥粉末、トマト果実由来の水溶性成分等とテストステロン増加作用の関係についてはこれまで報告されていない。 However, the relationship between the dry powder of tomato, the water-soluble component derived from tomato fruit, and the testosterone-increasing action has not been reported so far.
本発明の課題は、安全性の高いテストステロン増加剤を提供することである。 An object of the present invention is to provide a highly safe testosterone increasing agent.
前記課題を解決すべく、本発明者らは、安全性が確立されているトマトから調製したトマトの乾燥粉末、抽出物又はそれらの処理物を摂取することにより、テストステロンの低下を抑制できることを見出し、本発明を完成するに至った。
すなわち、本発明の要旨は以下のとおりである。
(1)トマトの乾燥粉末、抽出物又はそれらの処理物を含有するテストステロン増加剤。
(2)トマト果実由来の水溶性成分を含有する前記(1)に記載のテストステロン増加剤。
(3)実質的にリコペンを含有しない前記(2)に記載のテストステロン増加剤。
(4)実質的にトマト果実由来の非水溶性成分を含有しない前記(2)に記載のテストステロン増加剤。
(5)トマト果実由来の水溶性成分を含有し、実質的にリコペンを含有しないテストステロン増加剤。
(6)実質的にトマト果実由来の非水溶性成分を含有しない前記(5)に記載のテストステロン増加剤。
(7)食品として用いる前記(1)〜(6)のいずれかに記載のテストステロン増加剤。
In order to solve the above problems, the present inventors have found that a decrease in testosterone can be suppressed by ingesting a dry powder, an extract or a processed product thereof of tomato prepared from tomatoes whose safety has been established. , The present invention has been completed.
That is, the gist of the present invention is as follows.
(1) A testosterone increasing agent containing a dry powder of tomato, an extract or a processed product thereof.
(2) The testosterone increasing agent according to (1) above, which contains a water-soluble component derived from tomato fruit.
(3) The testosterone increasing agent according to (2) above, which does not substantially contain lycopene.
(4) The testosterone increasing agent according to (2) above, which does not substantially contain a water-insoluble component derived from tomato fruit.
(5) A testosterone-increasing agent containing a water-soluble component derived from tomato fruit and substantially free of lycopene.
(6) The testosterone increasing agent according to (5) above, which does not substantially contain a water-insoluble component derived from tomato fruit.
(7) The testosterone increasing agent according to any one of (1) to (6) above, which is used as a food.
本発明によれば、安全性の高いテストステロン増加剤を提供することができる。 According to the present invention, it is possible to provide a highly safe testosterone increasing agent.
本発明において、トマト(Solanum lycopersicum)としては、通常、果実の乾燥粉末、抽出物又はその処理物が用いられる。原料として用いるトマト果実としては、PAO(potential anti oxidant)活性が高いものを用いることが好ましい。このようなトマトは、極少培地多頻度少量給液法により栽培することにより得ることができる。極少培地多頻度少量給液法における一株当たりの培地量は、通常1000ml未満、好ましくは200〜500mlである。 In the present invention, as tomato (Solanum lycopersicum), a dry powder of fruit, an extract or a processed product thereof is usually used. As the tomato fruit used as a raw material, it is preferable to use one having high PAO (potential anti-oxidant) activity. Such tomatoes can be obtained by cultivating them by a method of supplying a very small amount of medium frequently and in a small amount. The amount of medium per strain in the ultra-small medium frequent small amount feeding method is usually less than 1000 ml, preferably 200 to 500 ml.
トマト果実の乾燥粉末としては、例えば、トマト果実を丸ごとピューレ化後、必要に応じて、濾過して不溶物を除去した後、乾燥粉末化して得られる粉末、トマト果実を乾燥後、常法により粉砕して得られる粉末、抽出物の乾燥粉末が挙げられる。 Examples of the dry powder of tomato fruit include a powder obtained by pureing the whole tomato fruit, filtering it to remove insoluble matter, and then drying the tomato fruit, and then drying the tomato fruit by a conventional method. Examples include powder obtained by crushing and dry powder of an extract.
トマト抽出物を得るために用いる溶媒としては、水;アルコール類、例えばメタノール、エタノール、プロパノール、ブタノール;エステル類、例えば酢酸エチル等の酢酸エステル;エーテル類、例えばエチルエーテル、ジオキサン;ケトン類、例えばアセトン等が挙げられる。抽出物を一旦溶媒除去して乾燥物として用いる場合には、前述した任意の溶媒を単独で又は混合して用いることができる。一方、抽出物を溶媒に溶解した状態で用いる場合には、人体に対して有害な作用を示さない溶媒を用いる必要があり、この場合には、水、エタノール又はこれらの混合物を用いることが好ましい。抽出に際して、トマト果実は、そのまま用いることができ、また乾燥後に破砕又は粉砕して溶媒との接触を高めることもできる。 Solvents used to obtain tomato extracts include water; alcohols such as methanol, ethanol, propanol, butanol; esters such as acetate such as ethyl acetate; ethers such as ethyl ether, dioxane; ketones such as ketones. Acetone and the like can be mentioned. When the extract is once removed from the solvent and used as a dried product, any of the above-mentioned solvents can be used alone or in combination. On the other hand, when the extract is used in a state of being dissolved in a solvent, it is necessary to use a solvent that does not have a harmful effect on the human body, and in this case, it is preferable to use water, ethanol or a mixture thereof. .. At the time of extraction, the tomato fruit can be used as it is, or it can be crushed or crushed after drying to enhance the contact with the solvent.
トマト果実1kg当り溶媒2〜4Lで抽出する。抽出温度は、室温ないし溶媒の常圧下での沸点の範囲内であり、抽出時間は、抽出温度等により異なるが、好ましくは、室温の場合24〜30時間、溶媒の常圧下での沸点で行う場合0.5〜2時間である。 Extract with 2-4 L of solvent per kg of tomato fruit. The extraction temperature is within the range of room temperature or the boiling point of the solvent under normal pressure, and the extraction time varies depending on the extraction temperature and the like, but is preferably performed at room temperature for 24 to 30 hours at the boiling point of the solvent under normal pressure. The case is 0.5 to 2 hours.
このようにして得られた抽出液は、必要に応じて、布、ステンレスフィルター、濾紙、濾過滅菌用フィルター等で濾過して不溶物、不純物等を除去して用いてもよい。また、濾過後の抽出液に、スプレードライ処理、フリーズドライ処理、超臨界処理等の処理を施してもよい。 The extract thus obtained may be used by filtering it with a cloth, a stainless steel filter, a filter paper, a filter for filtration sterilization or the like to remove insoluble matter, impurities and the like, if necessary. Further, the extracted extract after filtration may be subjected to a treatment such as a spray-drying treatment, a freeze-drying treatment, or a supercritical treatment.
前記のようにして得られる乾燥粉末、抽出物又はその処理物は、そのまま本発明のテストステロン増加剤の有効成分として用いることができる。また、当該抽出物等をイオン交換クロマトグラフィー、ゲル濾過クロマトグラフィー、透析等の各種精製手段により処理し、更に活性を高めた処理物として用いてもよい。
また、トマトの乾燥粉末、抽出物又はそれらの処理物を含有する本発明のテストステロン増加剤は、リコペン等のトマト果実由来の非水溶性成分を含有してもよいが、製剤上の理由等の点から、リコペン等のトマト果実由来の非水溶性成分を除去して、当該非水溶性成分を実質的に含有しない組成物として用いてもよい。
ここで、リコペン等のトマト果実由来の非水溶性成分を「実質的に含有しない」とは、当該非水溶性成分による影響がない程度に夾雑物として含有する場合を除外するものではない。
リコペン等のトマト果実由来の非水溶性成分を除去する方法としては、特に制限はないが、例えば、トマトの乾燥粉末、抽出物又はそれらの処理物を含有する組成物を遠心分離して、固形分を沈殿、除去して上澄み液を採取すればよい。
The dry powder, extract or processed product thereof obtained as described above can be used as it is as an active ingredient of the testosterone increasing agent of the present invention. Further, the extract or the like may be treated by various purification means such as ion exchange chromatography, gel filtration chromatography, dialysis and the like to be used as a treated product having further enhanced activity.
Further, the testosterone increasing agent of the present invention containing a dry powder of tomato, an extract or a processed product thereof may contain a water-insoluble component derived from tomato fruit such as lycopene, but for reasons such as formulation. From the point of view, the water-insoluble component derived from tomato fruit such as lycopene may be removed and used as a composition substantially free of the water-insoluble component.
Here, "substantially free of water-insoluble components derived from tomato fruits such as lycopene" does not exclude the case where they are contained as impurities to the extent that the water-insoluble components do not affect them.
The method for removing the water-insoluble component derived from tomato fruit such as lycopene is not particularly limited, but for example, a composition containing a dry powder of tomato, an extract or a processed product thereof is centrifuged and solidified. The minutes may be precipitated and removed, and the supernatant may be collected.
本発明のテストステロン増加剤は、トマトの乾燥粉末、抽出物又はそれらの処理物、あるいはこれらの組成物からリコペン等のトマト果実由来の非水溶性成分を除去して得られる、当該非水溶性成分を実質的に含有しない組成物を公知の食品用担体又は医薬用担体と組合せて製剤化することができる。投与形態としては、特に制限はなく、必要に応じ適宜選択されるが、一般には錠剤、カプセル剤、顆粒剤、細粒剤、散剤、液剤、シロップ剤、懸濁剤、乳剤、エリキシル剤等の経口剤として使用される。また、本発明のテストステロン増加剤は、注射剤、点滴剤、坐剤、吸入剤、経皮吸収剤、経粘膜吸収剤、貼付剤、軟膏剤等の非経口剤として使用してもよい。また、本発明のテストステロン増加剤は、食品、チューインガム、飲料等に添加して、いわゆる特定保健用食品又は機能性表示食品(例えば、男性ホルモン増加用食品、ストレス改善用食品、疲労回復用食品、男性更年期障害予防用食品)等とすることもできる。 The testosterone increasing agent of the present invention is obtained by removing a water-insoluble component derived from tomato fruit such as lycopene from a dry powder of tomato, an extract or a processed product thereof, or a composition thereof. A composition substantially free of the above can be formulated in combination with a known food carrier or pharmaceutical carrier. The dosage form is not particularly limited and may be appropriately selected as needed, but generally includes tablets, capsules, granules, fine granules, powders, liquids, syrups, suspensions, emulsions, elixirs and the like. Used as an oral preparation. In addition, the testosterone increasing agent of the present invention may be used as a parenteral agent such as an injection, a drip, a suppository, an inhalant, a transdermal absorbent, a transmucosal absorbent, a patch, and an ointment. Further, the testosterone increasing agent of the present invention is added to foods, chewing gums, beverages, etc., so-called foods for specified health use or foods with functional claims (for example, foods for increasing male hormones, foods for improving stress, foods for recovery from fatigue, etc. It can also be used as a food for preventing male menopausal disorders).
本発明のテストステロン増加剤の投与量は、患者の年令、体重、疾患の程度、投与経路により異なるが、経口投与では、トマトの乾燥粉末及び抽出物等では、乾燥粉末として、通常1日15〜500mgであり、投与回数は、通常、経口投与では1日1〜3回である。 The dose of the testosterone-increasing agent of the present invention varies depending on the age, body weight, degree of disease, and route of administration of the patient. The dose is ~ 500 mg, and the number of administrations is usually 1 to 3 times a day for oral administration.
経口剤は、例えばデンプン、乳糖、白糖、マンニット、カルボキシメチルセルロース、コーンスターチ、無機塩類等の賦形剤を用いて常法に従って製造される。 Oral preparations are prepared according to conventional methods using excipients such as starch, lactose, sucrose, mannitol, carboxymethyl cellulose, cornstarch, and inorganic salts.
前記の製剤には、適宜前記賦形剤の他に、結合剤、崩壊剤、界面活性剤、滑沢剤、流動性促進剤、矯味剤、着色剤、香料等を使用することができる。 In the above-mentioned preparation, in addition to the above-mentioned excipient, a binder, a disintegrant, a surfactant, a lubricant, a fluidity accelerator, a flavoring agent, a coloring agent, a fragrance and the like can be appropriately used.
結合剤の具体例としては、結晶セルロース、結晶セルロース・カルメロースナトリウム、メチルセルロース、ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルメチルセルロースフタレート、ヒドロキシプロピルメチルセルロースアセテートサクシネート、カルメロースナトリウム、エチルセルロース、カルボキシメチルエチルセルロース、ヒドロキシエチルセルロース、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、デキストリン、アルファー化デンプン、部分アルファー化デンプン、ヒドロキシプロピルスターチ、プルラン、ポリビニルピロリドン、アミノアルキルメタクリレートコポリマーE、アミノアルキルメタクリレートコポリマーRS、メタクリル酸コポリマーL、メタクリル酸コポリマー、ポリビニルアセタールジエチルアミノアセテート、ポリビニルアルコール、アラビアゴム、アラビアゴム末、寒天、ゼラチン、白色セラック、トラガント、精製白糖、マクロゴールが挙げられる。 Specific examples of the binder include crystalline cellulose, crystalline cellulose carmellose sodium, methyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, and carmellose sodium. , Ethyl cellulose, carboxymethyl ethyl cellulose, hydroxyethyl cellulose, wheat starch, rice starch, corn starch, potato starch, dextrin, pregelatinized starch, partially pregelatinized starch, hydroxypropyl starch, purulan, polyvinylpyrrolidone, aminoalkyl methacrylate copolymer E, aminoalkyl Examples thereof include methacrylate copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer, polyvinyl acetal diethylaminoacetate, polyvinyl alcohol, gum arabic, rubber arabic powder, agar, gelatin, white cellac, tragant, purified sucrose, and macrogol.
崩壊剤の具体例としては、結晶セルロース、メチルセルロース、低置換度ヒドロキシプロピルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム、クロスカルメロースナトリウム、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、部分アルファー化デンプン、ヒドロキシプロピルスターチ、カルボキシメチルスターチナトリウム、トラガントが挙げられる。 Specific examples of the disintegrant include crystalline cellulose, methyl cellulose, low-substituted hydroxypropyl cellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, wheat starch, rice starch, corn starch, potato starch, and partial pregelatinization. Examples include starch, hydroxypropyl starch, sodium carboxymethyl starch and tragant.
界面活性剤の具体例としては、大豆レシチン、ショ糖脂肪酸エステル、ステアリン酸ポリオキシル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンポリオキシプロピレングリコール、セスキオレイン酸ソルビタン、トリオレイン酸ソルビタン、モノステアリン酸ソルビタン、モノパルミチン酸ソルビタン、モノラウリン酸ソルビタン、ポリソルベート、モノステアリン酸グリセリン、ラウリル硫酸ナトリウム、ラウロマクロゴールが挙げられる。 Specific examples of surfactants include soybean lecithin, sucrose fatty acid ester, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, and sorbitan monostearate. , Polysorbate monopalmitate, sorbitan monolaurate, polysorbate, glycerin monostearate, sodium lauryl sulfate, lauromacrogol.
滑沢剤の具体例としては、コムギデンプン、コメデンプン、トウモロコシデンプン、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム、含水二酸化ケイ素、軽質無水ケイ酸、合成ケイ酸アルミニウム、乾燥水酸化アルミニウムゲル、タルク、メタケイ酸アルミン酸マグネシウム、リン酸水素カルシウム、無水リン酸水素カルシウム、ショ糖脂肪酸エステル、ロウ類、水素添加植物油、ポリエチレングリコールが挙げられる。 Specific examples of lubricants include wheat starch, rice starch, corn starch, stearic acid, calcium stearate, magnesium stearate, hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, dry aluminum hydroxide gel, talc, etc. Examples thereof include magnesium aluminometasilicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, sucrose fatty acid ester, braces, hydrogenated vegetable oil, and polyethylene glycol.
流動性促進剤の具体例としては、含水二酸化ケイ素、軽質無水ケイ酸、乾燥水酸化アルミニウムゲル、合成ケイ酸アルミニウム、ケイ酸マグネシウムが挙げられる。 Specific examples of the fluidity accelerator include hydrous silicon dioxide, light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, and magnesium silicate.
また、本発明のテストステロン増加剤は、液剤、シロップ剤、懸濁剤、乳剤、エリキシル剤として投与する場合には、矯味矯臭剤、着色剤を含有してもよい。
本発明のテストステロン増加剤の製造原料であるトマトは、食用に供されており、安全性は確立されている。
In addition, the testosterone increasing agent of the present invention may contain a flavoring agent and a coloring agent when administered as a liquid agent, a syrup agent, a suspending agent, an emulsion, or an elixir agent.
The tomato, which is a raw material for producing the testosterone increasing agent of the present invention, is edible and its safety has been established.
以下、本発明を実施例により説明するが、本発明は、以下の実施例に限定されるものではない。
(製造例1)トマト粉末の調製
トマト(Solanum lycopersicum)果実を丸ごとピューレ化した後、乾燥粉末化してトマト粉末を得た。
ここで用いたトマト果実は、極少培地多頻度少量給液法による栽培(一株当たりの培地量:300ml、培地の種類:ココナツの実の繊維や粉末を乾かして粉砕したヤシガラ培地)で得られたものであり、株式会社うまヘルシーから入手した。
Hereinafter, the present invention will be described with reference to Examples, but the present invention is not limited to the following Examples.
(Production Example 1) Preparation of tomato powder The whole tomato (Solanum lycopersicum) fruit was pureed and then dried and powdered to obtain tomato powder.
The tomato fruits used here are obtained by cultivating with a very small amount of medium and a small amount of liquid feeding method (medium amount per plant: 300 ml, medium type: coconut fruit fibers and powder dried and crushed coconut husk medium). It was obtained from Uma Healthy Co., Ltd.
(実施例1)トマト粉末によるテストステロン分泌能の増加効果
加齢やストレスにより精巣(睾丸)からの男性ホルモン(テストステロン)分泌能が低下することが知られている。そこで、以下の試験では、精巣障害モデル及びストレスモデルのマウスによる2つのモデル実験おいて、トマト粉末によるテストステロン分泌能の増加効果を検討した。
(Example 1) Effect of increasing testosterone secretion by tomato powder It is known that the secretion of male hormone (testosterone) from the testis (testis) decreases due to aging and stress. Therefore, in the following tests, the effect of tomato powder on increasing testosterone secretion was examined in two model experiments using a testis disorder model and a stress model mouse.
(試験方法1)精巣障害モデル
マウス(ddY系、オス、7週齢)を3群に分け、第1群は、通常食(MF,オリエンタル酵母)を摂取させ、何も処置しない群、第2群は、通常食を摂取させ、シスプラチン(2.5mg/kg)を腹腔に投与した群、第3群は、10%トマト粉末(製造例1で得られたトマト粉末)を含む試験食を摂取させ、シスプラチン(2.5mg/kg)を腹腔に投与した群とした。各群はn=3とした。飼育開始1週間後、精巣を取り出し、初代培養法にて精巣細胞を培養した。一夜、培養後、刺激剤としてヒト絨毛性ゴナドトロピン(hCG)(1U)を添加して、精巣からのテストステロン分泌量を、EIA法にて定量測定した。
(Test method 1) Testicular disorder model mice (ddY system, male, 7 weeks old) were divided into 3 groups, the 1st group was ingested with a normal diet (MF, oriental yeast), and no treatment was performed, the 2nd group. The group ingested a normal diet and cisplatin (2.5 mg / kg) was intraperitoneally administered, and the third group ingested a test diet containing 10% tomato powder (tomato powder obtained in Production Example 1). The group was divided into a group in which cisplatin (2.5 mg / kg) was intraperitoneally administered. Each group was set to n = 3. One week after the start of breeding, the testis was taken out and the testis cells were cultured by the primary culture method. After culturing overnight, human chorionic gonadotropin (hCG) (1U) was added as a stimulant, and the amount of testosterone secreted from the testis was quantitatively measured by the EIA method.
(試験方法2)ストレスモデル
マウス(ddY系、オス、7週齢)を3群に分け、第1群は、通常食(MF,オリエンタル酵母)を摂取させ、何も処置しない群、第2群は、通常食を摂取させた群、第3群は、10%トマト粉末(製造例1で得られたトマト粉末)を含む試験食を摂取させた。第2群と第3群は、飼育5〜7日目に、拘束ストレス処理を行った。拘束は、通気孔を多数開けたプラスチックチューブ(50ml)に約12時間入れた。各群はn=3とした。飼育開始1週間後、精巣を取り出し、初代培養法にて精巣細胞を培養した。一夜、培養後、刺激剤としてヒト絨毛性ゴナドトロピン(hCG)(1U)を添加して、精巣からのテストステロン分泌量を免疫測定(EIA)法にて定量測定した。
(Test method 2) Stress model mice (ddY system, male, 7 weeks old) were divided into 3 groups, and the 1st group was ingested with a normal diet (MF, oriental yeast) and no treatment was performed, the 2nd group. Was fed a normal diet, and the third group was fed a test diet containing 10% tomato powder (tomato powder obtained in Production Example 1). The second and third groups were subjected to restraint stress treatment on the 5th to 7th days of breeding. Restraint was placed in a plastic tube (50 ml) with many vents for about 12 hours. Each group was set to n = 3. One week after the start of breeding, the testis was taken out and the testis cells were cultured by the primary culture method. After culturing overnight, human chorionic gonadotropin (hCG) (1U) was added as a stimulant, and the amount of testosterone secreted from the testis was quantitatively measured by the immunoassay (EIA) method.
(試験結果)
精巣障害モデルの結果を図1に示す。精巣障害を起こさせたところ、精巣からのテストステロン分泌量は、シスプラチンを投与し、通常食を摂取させた群では、無処置群に比して、有意に低下し、シスプラチンによる精巣障害がおこりテストステロン分泌量の低下がみられた。一方、シスプラチンを投与し、トマト粉末を摂取させた群では、シスプラチンを投与し、通常食を摂取させた群に比し、有意に増加し、シスプラチン非投与の無処置群とほぼ同レベルまで、精巣障害を抑制できることが示された。
(Test results)
The results of the testicular disorder model are shown in FIG. When testicular disorders were caused, the amount of testosterone secreted from the testes was significantly lower in the group to which cisplatin was administered and fed with a normal diet than in the untreated group, and cisplatin-induced testosterone disorders occurred and testosterone. There was a decrease in secretion. On the other hand, in the group to which cisplatin was administered and tomato powder was ingested, the increase was significantly higher than that in the group to which cisplatin was ingested and the normal diet was ingested, and to almost the same level as the untreated group in which cisplatin was not administered. It was shown that testicular damage can be suppressed.
慢性ストレスモデルの結果を図2に示す。精巣からのテストステロン分泌量は、通常食を摂取後、拘束ストレス処理を行った群(慢性ストレス群、第2群)では、慢性ストレスを与えない無処置群(第1群)に比し、テストステロン分泌量が有意に低下し、精巣機能低下が観察された。一方、拘束ストレス負荷とともにトマト粉末を摂取させておいた群(トマト粉末摂取群)では、通常食を摂取後、拘束ストレス処理を行った群(慢性ストレス群、第2群)に比し、テストステロン分泌量が有意に増加し、ストレスによる精巣機能低下を抑制できることが示唆された。 The results of the chronic stress model are shown in FIG. The amount of testosterone secreted from the testes was higher in the group that received restraint stress treatment after ingesting a normal diet (chronic stress group, group 2) than in the untreated group that did not give chronic stress (group 1). The amount of secretion was significantly reduced, and testicular dysfunction was observed. On the other hand, in the group in which tomato powder was ingested together with the restraint stress load (tomato powder intake group), testosterone was compared with the group in which restraint stress treatment was performed after ingesting a normal diet (chronic stress group, second group). It was suggested that the amount of secretion was significantly increased and that the decrease in testosterone function due to stress could be suppressed.
(効果)
加齢により男性ホルモン量は徐々に低下し、性腺機能のみならず筋力低下、活力低下等の男性更年期障害といわれる様々な症状があらわれる。トマト粉末の摂取により、これら更年期症状の防止が期待できる。また、慢性ストレスによる男性ホルモン量低下に対しても同様に効果があることから、ストレス軽減効果も認められる。
(effect)
With aging, the amount of androgen gradually decreases, and various symptoms called male menopause such as hypogonadism, muscle weakness, and vitality appear. Ingestion of tomato powder can be expected to prevent these menopausal symptoms. In addition, since it has the same effect on the decrease in the amount of male hormone due to chronic stress, a stress-reducing effect is also recognized.
超高齢・ストレス社会において、寝たきり防止のための方策には、まずサルコペニアといわれる筋力低下を防止することが必要とされ、男性ホルモン低下の防止が重要と考えられている。また、女性においても副腎アンドロゲンといわれるホルモンが同様の作用を担うとされる。更に、意欲・活力等の精神的活動に対しても男性ホルモンが影響することから、トマト粉末摂取がこれらQOLを維持する効果が期待される。 In a super-aged and stressed society, it is first necessary to prevent muscle weakness called sarcopenia as a measure to prevent bedridden, and it is considered important to prevent androgen decrease. In women, a hormone called adrenal androgen is said to have a similar effect. Furthermore, since male hormones also affect mental activities such as motivation and vitality, ingestion of tomato powder is expected to have the effect of maintaining these QOLs.
(参考例1)PAO活性に対するトマトの栽培法の影響
PAO(potential anti oxidant)活性に対するトマトの栽培法の影響を検討するため、以下の2つの条件で栽培を行った。
試験区:極少培地多頻度少量給液法による栽培(一株当たりの培地量:300ml)
対照区:バック栽培(一株当たりの培地量:4000ml以上)
試験区は、根域を極端に制限することで根に自然にストレスが掛かり、トマト栽培の熟練者でなくても比較的容易にトマトの品質が上がるとされている栽培である。
試験区で栽培されたトマトのPAO活性が慣行栽培(対照区栽培)によってできたトマトに比べどれほど上がるかを分析した。
(Reference Example 1) Effect of tomato cultivation method on PAO activity In order to examine the effect of tomato cultivation method on PAO (potential antioxidant) activity, cultivation was carried out under the following two conditions.
Test group: Cultivation by the ultra-low medium frequency small amount liquid supply method (medium amount per strain: 300 ml)
Control group: Back cultivation (medium amount per strain: 4000 ml or more)
The test plot is a cultivation in which the roots are naturally stressed by extremely limiting the root area, and it is said that the quality of tomatoes can be improved relatively easily even if the person is not an expert in tomato cultivation.
It was analyzed how much the PAO activity of tomatoes cultivated in the test plot was higher than that of tomatoes cultivated by conventional cultivation (control plot cultivation).
(1)試料の調製
トマト(試験区、対照区、それぞれ12個ずつ)を4つ切りにし、その4分の1を秤量後、ポリ試験管(50ml)に入れ、ポリトロンホモジナイザーで均一化させ、遠心分離機(5,000rpm,10分)にて、固形分を沈殿させた。上澄み液を採取し、−20℃にて保存した。測定前に、その一部をとり、0.45μmのフィルターにて濾過し、僅かに残る不溶物を除去し、これをPAO活性測定用試料とした。
(1) Preparation of sample Cut tomatoes (12 each in a test group and a control group) into 4 pieces, weigh a quarter of the tomatoes, put them in a poly test tube (50 ml), and homogenize them with a polytron homogenizer. The solid content was precipitated by a centrifuge (5,000 rpm, 10 minutes). The supernatant was collected and stored at −20 ° C. Before the measurement, a part thereof was taken and filtered through a 0.45 μm filter to remove a slight amount of insoluble matter, which was used as a sample for measuring PAO activity.
(2)PAO活性の測定
PAO抗酸化能測定キット(日研ザイル(株)日本老化制御研究所)により、使用説明書に記載された方法によりPAO活性の測定を行った。
標準物質2mM尿酸を適宜希釈し、希釈系列を作製した。試験管6本に濃度の異なる標準物質10μl、及び水390μlを添加し希釈した。また別途、試験管に前記トマト試料(果汁)10μl及び水390μlをとり希釈した。マイクロプレートに、これら希釈標準物質及び希釈試料を添加し、各ウェルに銅試薬50μlを添加撹拌し、3分反応させた。反応停止薬を各ウェルに添加撹拌し、マイクロプレートリーダーで490nmにおける吸光度を測定した。標準物質の検量線に基づき、試料の尿酸相当濃度を求め、これに銅還元力係数2189を乗し、これをPAO活性値として表した。
(2) Measurement of PAO activity PAO activity was measured by the method described in the instruction manual using the PAO antioxidant capacity measurement kit (Nikken Zile Co., Ltd. Japan Aging Control Laboratory).
The
結果を図3に示す。
PAO抗酸化活性は、試験区と対照区で有意の差がみられた。試料(果汁)は測定の都合上、濾過が必要であったため、ほぼ無色かつ水溶性であり、リコペン、カロテン、ビタミンK等の脂溶性物質のPAO抗酸化活性に対する寄与は少ないと推測される。水溶性の抗酸化物質によるものと考えられる。
The results are shown in FIG.
The PAO antioxidant activity was significantly different between the test group and the control group. Since the sample (fruit juice) needed to be filtered for the convenience of measurement, it was almost colorless and water-soluble, and it is presumed that the contribution of fat-soluble substances such as lycopene, carotene, and vitamin K to the PAO antioxidant activity was small. Probably due to water-soluble antioxidants.
PAO抗酸化活性をトマト平均1個重量あたりに換算したところ、試験区と対照区で有意の差がみられた。試験区でトマトの重量が減少した分を水分と仮定して、平均重量をPAO活性に乗じたところ、この分を考慮してもPAO活性は高かった。
対照区のPAO活性の最大値が2.16μmol/gであるのに対し、試験区のPAO活性の最大値は3.07μmol/gであった。
したがって、PAO活性が2.3〜3.5μmol/gのトマトを用いるのが好ましく、2.5〜3.5μmol/gのトマトを用いるのが更に好ましい。
When the PAO antioxidant activity was converted to the average weight of one tomato, a significant difference was observed between the test group and the control group. Assuming that the amount of decrease in tomato weight in the test plot was water, the average weight was multiplied by the PAO activity, and the PAO activity was high even when this amount was taken into consideration.
The maximum PAO activity of the control group was 2.16 μmol / g, whereas the maximum PAO activity of the test group was 3.07 μmol / g.
Therefore, it is preferable to use tomatoes having a PAO activity of 2.3 to 3.5 μmol / g, and more preferably tomatoes having a PAO activity of 2.5 to 3.5 μmol / g.
(実施例2)トマトの男性ホルモン分泌増加効果
(試験方法1)ストレスモデル
マウス(ddY系、オス、7週齢)を3群に分け、第1群は、無処置群とし、第2群と第3群は、飼育5〜7日目に、拘束ストレス処理を行った。拘束は、通気孔を多数開けたプラスチックチューブ(50ml)に約12時間入れた。第3群は、トマト果汁を飲水の代わりに摂取させた。トマト果汁は、市販ミキサーにてトマトを粉砕した後、遠心分離し、果肉等の不溶物を除去した透明な黄色の果汁とした。なお、これにはリコペンが殆ど含まれていない。いずれの群も、通常食(MF,オリエンタル酵母)を摂取させた。各群はn=4とした。1週間後、精巣を取り出し、初代培養法にて精巣細胞を調製した。一夜、培養後、細胞を洗浄後、3時間培養して培地を採取し、培地中のテストステロン分泌量を免疫測定(EIA)法にて定量測定した。また、精巣の一部をリン酸緩衝液にて抽出し、Flohe とGunzlerらの方法(Flohe,L., Gunzler,W.A., Schock, H.H., Glutathione peroxidase:a selenoenzyme.FEBS Lett., 32:132-134 (1973))により、グルタチオンペルオキシダーゼ活性(GPx)を測定した。
(Example 2) Effect of increasing androgen secretion of tomatoes (test method 1) Stress model mice (ddY system, male, 7 weeks old) were divided into 3 groups, and the first group was an untreated group and the second group. The third group was subjected to restraint stress treatment on the 5th to 7th days of breeding. Restraint was placed in a plastic tube (50 ml) with many vents for about 12 hours. The third group ingested tomato juice instead of drinking water. The tomato juice was obtained by crushing tomatoes with a commercially available mixer and then centrifuging to obtain a transparent yellow juice from which insoluble matter such as pulp was removed. It should be noted that this contains almost no lycopene. Both groups were fed a normal diet (MF, oriental yeast). Each group was set to n = 4. After 1 week, the testes were removed and testis cells were prepared by the primary culture method. After culturing overnight, the cells were washed, and the medium was collected by culturing for 3 hours, and the amount of testosterone secreted in the medium was quantitatively measured by an immunoassay (EIA) method. In addition, a part of the testis was extracted with phosphate buffer, and the method of Flohe and Gunzler et al. (Flohe, L., Gunzler, WA, Schock, HH, Glutathione peroxidase: a selenoenzyme.FEBS Lett., 32: 132- Glutathione peroxidase activity (GPx) was measured by 134 (1973)).
(試験方法2)ストレスモデル
マウス(ddY系、オス、7週齢)を3群に分け、第1群は、無処置群とし、第2群と第3群は、飼育5〜7日目に、拘束ストレス処理を行った。拘束は、通気孔を多数開けたプラスチックチューブ(50ml)に約12時間入れた。第3群は、飲水として1%ビタミンC水溶液を摂取させた。いずれの群も、通常食(MF, オリエンタル酵母)を摂取させた。各群はn=4とした。1週間後、精巣を取り出し、初代培養法にて精巣細胞を調製した。一夜、培養後、細胞を洗浄後、3時間培養して培地を採取し、培地中のテストステロン分泌量を免疫測定(EIA)法にて定量測定した。
(Test method 2) Stress model mice (ddY system, male, 7 weeks old) were divided into 3 groups, the 1st group was an untreated group, and the 2nd and 3rd groups were on the 5th to 7th day of breeding. , Restraint stress treatment was performed. Restraint was placed in a plastic tube (50 ml) with many vents for about 12 hours. The third group was fed with a 1% aqueous vitamin C solution as drinking water. Both groups were fed a normal diet (MF, Oriental yeast). Each group was set to n = 4. After 1 week, the testes were removed and testis cells were prepared by the primary culture method. After culturing overnight, the cells were washed, and the medium was collected by culturing for 3 hours, and the amount of testosterone secreted in the medium was quantitatively measured by an immunoassay (EIA) method.
(試験結果)
トマト果汁摂取の効果をストレスモデルで調べたところ、図4に示すように、ストレス負荷により精巣細胞からのテストステロン分泌量は、無処置群に比して低下したが、その間、トマト果汁を摂取させた群ではテストステロン分泌量が有意に増加し、ストレスによる精巣機能低下を抑制していることが示唆された。精巣のグルタチオンペルオキシダーゼ活性を調べたところ、果汁摂取群では慢性ストレス群より、有意の増加がみられた(図5)。
(Test results)
When the effect of ingestion of tomato juice was examined by a stress model, as shown in FIG. 4, the amount of testosterone secreted from testis cells decreased due to stress load as compared with the untreated group, but during that period, tomato juice was ingested. In the group, testosterone secretion was significantly increased, suggesting that stress-induced testicular dysfunction was suppressed. When the glutathione peroxidase activity of the testis was examined, a significant increase was observed in the fruit juice intake group as compared with the chronic stress group (Fig. 5).
また、ビタミンC摂取の効果を同様のストレスモデルで調べたところ、図6に示すように、ストレス負荷により精巣細胞からのテストステロン分泌量は、無処置群に比して低下したが、ビタミンCを摂取させた群ではテストステロン分泌量が僅かに増加した。 In addition, when the effect of vitamin C intake was investigated using a similar stress model, as shown in FIG. 6, the amount of testosterone secreted from the testosterone cells decreased due to stress loading as compared with the untreated group, but vitamin C was added. Testosterone secretion increased slightly in the ingested group.
(考察)
実施例1のリコペンを含むトマト粉末摂取によるテストステロン分泌低下抑制効果に加え、本実施例では、リコペンをほとんど含まないトマト果汁について、ストレスモデルにおいて、同様のテストステロン分泌低下抑制(増加)効果が認められた。そのうち、果汁に含まれるビタミンCを摂取させた同様の試験で、僅かに効果がみられたことから、トマト果汁のテストステロン増加作用はビタミンCが一部、寄与していると考えられるが、ビタミンC以外の水溶性成分の寄与も示唆された。本実施例の条件下では、抗酸化活性をもつビタミンCでは有意の増加を認めなかったが、精巣の抗酸化活性のうちグルタチオンペルオキシダーゼ活性が、果汁摂取により有意に増加したことから、果汁に含まれる抗酸化活性をもつ水溶性成分がテストステロン分泌に影響したことが示唆された。
(Discussion)
In addition to the effect of suppressing the decrease in testosterone secretion by ingesting tomato powder containing lycopene in Example 1, in this example, the same effect of suppressing (increasing) the decrease in testosterone secretion was observed in the stress model for tomato juice containing almost no lycopene. rice field. Among them, a similar test in which vitamin C contained in fruit juice was ingested showed a slight effect. Therefore, it is considered that vitamin C partially contributes to the testosterone-increasing effect of tomato juice. The contribution of water-soluble components other than C was also suggested. Under the conditions of this example, no significant increase was observed in vitamin C having antioxidant activity, but glutathione peroxidase activity among the antioxidant activity of the testis was significantly increased by ingestion of fruit juice, and thus it was contained in fruit juice. It was suggested that the water-soluble component with antioxidant activity affected testosterone secretion.
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015234230 | 2015-11-30 | ||
JP2015234230 | 2015-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017105746A JP2017105746A (en) | 2017-06-15 |
JP6915774B2 true JP6915774B2 (en) | 2021-08-04 |
Family
ID=59060428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016111367A Active JP6915774B2 (en) | 2015-11-30 | 2016-06-02 | Testosterone increaser |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6915774B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102371575B1 (en) * | 2019-12-13 | 2022-03-08 | 주식회사 봄헬스케어 | Food Composition for Neutered Companion Animal |
JP7361076B2 (en) * | 2020-08-13 | 2023-10-13 | 佳 川戸 | testosterone booster |
-
2016
- 2016-06-02 JP JP2016111367A patent/JP6915774B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017105746A (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180103836A (en) | Special nutritional or therapeutic formulations containing a mixture of grapes and blueberries | |
JP2005154432A (en) | Treated material of acerola containing polyphenol and/or vitamin c | |
JP6915774B2 (en) | Testosterone increaser | |
JP2013151451A (en) | Antioxidation/antiallergic agent containing extract of impatiens | |
JP2005185188A (en) | Composition containing treated product of acerola and l-carnitine | |
KR20110068958A (en) | Pharmaceutical composition for improving obesity which comprises extract of lithospermum erythrorhizon as an active component | |
US20070003685A1 (en) | Prostacyclin production-increasing agent and blood flow enhancer | |
Garrido et al. | Characterization and trials of a jerte valley cherry product as a natural antioxidant-enriched supplement. | |
JP2012121840A (en) | Blood triglyceride level rise inhibitor | |
KR101092197B1 (en) | Food composition for improving fatty liver which comprises extract of tomato plant as an active component | |
KR101076185B1 (en) | Pharmaceutical composition for improving fatty liver which comprises extract of tomato plant as an active component | |
KR101134251B1 (en) | Food composition for improving obesity which comprises extract of torilis japonica as an active component | |
JP2005220100A (en) | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink | |
JP2015025008A (en) | Anti-glycation composition | |
JP2011074062A (en) | Anti-i type allergic agent | |
JP6320715B2 (en) | Alcoholic fatty liver preventive and therapeutic agent | |
JP5279163B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent and food and drink | |
KR101076583B1 (en) | Food composition for improving fatty liver which comprises extract of lithospermum erythrorhizon as an active component | |
WO2021106857A1 (en) | Composition for preventing or relieving uresiesthesia stress, and composition for improving sleep | |
JP2009227622A (en) | Therapeutic agent | |
JP4714438B2 (en) | Anti-fatigue agent and food and drink containing the same | |
JP2007006839A (en) | Frozen dessert containing royal jelly, pine bark extracted product and nucleic acid | |
JP2005104841A (en) | Active oxygen scavenger and method for producing the same | |
KR20220079175A (en) | Anti-inflammatory composition containing wheat germ extract | |
KR101076200B1 (en) | Pharmaceutical composition for improving obesity which comprises extract of tomato plant as an active component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20160627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160627 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20160627 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210705 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6915774 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |